Arie Roth, MD; Hylton I. Miller, MB; Bernard Beihassen, MD; Shlomo Laniado, MD
This content is PDF only. Please click on the PDF icon to access.
To the editor: Verapamil hydrochloride, a calcium antagonist, has been widely used for more than 25 years as an antianginal (1) and antiarrhythmic drug (2). Reports of verapamil's side effects (3) and acute intoxication (4, 5) are few and include various neurologic, cardiovascular, and metabolic derangements.
Slow-release verapamil hydrochloride (Calan, Searle and Company, San Juan, Puerto Rico) has been recently marketed to replace divided doses of verapamil for patients' convenience. We report an acute adverse reaction to a single dose of slow-release verapamil in a patient after well-tolerated, long-term treatment with regular verapamil.
A 66-year-old thin, nondiabetic white woman with
Roth A, Miller HI, Beihassen B, et al. Slow-Release Verapamil and Hyperglycemic Metabolic Acidosis. Ann Intern Med. 1989;110:171–172. doi: https://doi.org/10.7326/0003-4819-110-2-171_2
Download citation file:
Published: Ann Intern Med. 1989;110(2):171-172.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use